Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/acta.0.0440398 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment.
Cancers (Basel)
January 2025
UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.
Endocrine therapies that comprise anti-estrogens and aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive (ER+) (Luminal A) breast cancer-the most prevalent subtype. However, the emergence of resistance restricts their success by causing tumor relapse and re-growth, which demands a switch towards other therapeutic approaches in order to minimize or overcome resistance. Indeed, this clinical limitation highlights the search for new molecules to improve cancer treatment.
View Article and Find Full Text PDFSurface plasmon resonance detection of anti-cancer drug flutamide by graphitic carbon nitride/chitosan nanocomposite.
Sci Rep
January 2025
Faculty of Electrical and Computer Engineering, University of Tabriz, Tabriz, Iran.
The g-C3N4/CS biosensor was designed, fabricated, and tested using compounds such as glucose, urine, lactose, and flutamide at a molarity of 10 µM, which could demonstrate a high sensitivity of 200 μm-1 for flutamide. Powerful effective medium theory and FDTD simulation were used to predict the most favorable mode and plasmonic properties of a graphite carbon nitride and chitosan nanocomposite. The research also explores the characteristics of surface plasmon resonance exhibited by the nanocomposite as the chitosan content is adjusted.
View Article and Find Full Text PDF[A CASE OF SEVERE DRUG INDUCED ERUPTION AFTER APALUTAMIDE USE FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, WHICH WAS DETERIORATED FROM TEMPORARY REMISSION AFTER DRUG WITHDRAWAL].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Osaka Medical and Pharmaceutical University Faculty of Medicine.
A 70-years-old man with metastatic hormone-sensitive prostate cancer received the apalutamide, an oral androgen receptor signaling inhibitor. On day10 after drug initiation, fever and skin rash appeared on his whole-body surface. He stopped taking the drug on day18 and skin symptoms temporarily improved about 7 days after discontinuation.
View Article and Find Full Text PDF[UPFRONT DOCETAXEL WITH ANDROGEN DEPRIVATION THERAPY IN MALES WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: RESULTS OF A SINGLE-INSTITUTION SERIES].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Jikei University of Medicine.
(Objective) This study aimed at evaluating the efficacy and safety of upfront docetaxel (DTX) treatment and androgen deprivation therapy (ADT) in male patients with high-volume metastatic castration-sensitive prostate cancer (HV-mCSPC). (Methods) This retrospective study was conducted using the medical records of 30 patients treated for HV-mCSPC by using upfront DTX treatment along with ADT at Atsugi City Hospital between December 2015 and December 2022. The patient characteristics, demographics, oncological outcomes, adverse events, and sequential therapy were evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!